Table 1.
Baseline demographic and clinical characteristics
| Normal baseline CRP (<5 mg/L) |
Elevated baseline CRP (≥5 mg/L) |
|||
| Pooled secukinumab 150 mg (N=72) |
Pooled placebo (N=71) |
Pooled secukinumab 150 mg (N=125) |
Pooled placebo (N=124) |
|
| Age (years), mean (SD) | 42.3 (10.5) | 45.3 (13.2) | 39.9 (12.7) | 42.2 (12.3) |
| Male, n (%) | 39 (54.2) | 47 (66.2) | 91 (72.8) | 93 (75.0) |
| Weight (kg), mean (SD) | 74.5 (14.6) | 76.4 (13.8) | 79.2 (18.4) | 79.0 (15.3) |
| Caucasian, n (%)* | 50 (69.4) | 51 (71.8) | 88 (70.4) | 100 (80.6) |
| Time since AS diagnosis (years), mean (SD) | 5.9 (7.2) | 8.1 (9.9) | 7.2 (7.5) | 7.3 (8.3) |
| Positive for HLA-B27, n (%) | 44 (61.1) | 53 (74.6) | 99 (79.2) | 95 (76.6) |
| TNFi-naïve, n (%) | 52 (72.2) | 39 (54.9) | 84 (67.2) | 94 (75.8) |
| Concomitant methotrexate use, n (%) | 9 (12.5) | 7 (9.9) | 16 (12.8) | 17 (13.7) |
| hsCRP (mg/L), median (minimum‒maximum) | 2.1 (0.2‒4.9) | 1.9 (0.2‒4.9) | 16.8 (5.0‒237.0) | 14.9 (5.0‒146.8) |
| Total BASDAI score, mean (SD) | 6.7 (1.4) | 6.6 (1.6) | 6.3 (1.6) | 6.6 (1.4) |
| PtGA of disease activity (0‒100 mm), mean (SD)† | 68.0 (17.4) | 66.9 (19.3) | 63.7 (19.1) | 68.4 (16.7) |
*Race was self-assessed.
†Disease activity was scored on a visual-analog scale from 0 (no disease activity) to 100 mm (the most severe disease activity).
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HLA, human leucocyte antigen; N, number of patients in this pooled study; PtGA, patients global assessment; TNFi, tumor necrosis factor inhibitor; hsCRP, high sensitivity CRP.